SecurityMBVX / MabVax Therapeutics Holdings, Inc. (55414P108)
Institutional Owners5
Institutional Shares3,963,514 - 44.23%
Common Shares Outstanding8,961,840 shares (as of 2017-12-31)
Institutional Value$ 69,000 USD

Institutional Stock Ownership and Shareholders

MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) has 5 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,963,514 shares. Largest shareholders include Honig Barry C, Stetson John, Frost Phillip Md Et Al, Hansen John David, and Virtu Financial LLC.
MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-03 13F-HR BRIGHTON JONES LLC 10,000 0 -100.00 7 0 -100.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 18,996 0 -100.00 13 0 -100.00
2018-03-02 SC 13D/A Hansen John David 391,987
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 12,400 0 -100.00 9 0 -100.00
2018-02-14 13F-HR MORGAN STANLEY 374 0 -100.00 0 0
2018-05-08 13F-HR Lakeview Capital Partners, LLC 15,000 0 -100.00 11 0 -100.00
2018-05-15 13F-HR DEUTSCHE BANK AG\ 3 0 -100.00 0 0
2018-02-12 SC 13D Stetson John 854,682 1,204,352 40.91
2018-05-09 13F-HR Centerpoint Advisors, Llc 609 0 -100.00 0 0
2018-04-24 13F-HR Delaney Dennis R 10,000 0 -100.00 7 0 -100.00
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 7 0 -100.00 0 0
2018-05-15 13F-HR CLS Investments, LLC 1,000 0 -100.00 1 0 -100.00
2018-05-15 13F-HR UBS Group AG 17,547 0 -100.00 12 0 -100.00
2018-01-30 SC 13G/A FROST PHILLIP MD ET AL 422,334 1,059,157 150.79
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 3 0 -100.00 0 0
2018-04-20 13F-HR Biomark Capital Management Co. LLC 26,708 0 -100.00 19 0 -100.00
2018-05-09 13F-HR Cambridge Investment Research Advisors, Inc. 3,058,703 0 -100.00 2,141 0 -100.00
2018-02-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 30,798 0 -100.00 20 0 -100.00
2018-02-16 SC 13D/A Honig Barry C 1,208,904 1,208,904 0.00
2018-02-09 13F-HR Virtu Financial LLC 99,114 69

Related Articles

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics Analysis and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...

Related News Stories

BRIEF-MabVax Therapeutics Says Reverse Stock Split Is Scheduled To Be Effective With Opening Of Trading On Feb 16

2018-02-15 reuters
* MABVAX THERAPEUTICS SCHEDULES PREVIOUSLY ANNOUNCED 1-FOR-3 REVERSE STOCK SPLIT TO REGAIN COMPLIANCE WITH NASDAQ‘S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT (13-0)

MabVax Therapeutics (MBVX) Presents At BIO CEO & Investor Conference - Slideshow

2018-02-13 seekingalpha
The following slide deck was published by MabVax Therapeutics Holdings, Inc. in conjunction with this event. (13-0)

BRIEF-MabVax Therapeutics Announces Positive Interim Data From Trial of MVT-5873

2018-02-12 reuters
* MABVAX THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM EXPANDED COHORT IN PHASE 1 TRIAL EVALUATING MVT-5873 IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN PANCREATIC CANCER (13-0)

CUSIP: 55414P108